BLCM - Bellicum Pharma reports positive BPX-601 data in prostate cancer; secures $35M capital

Bellicum Pharmaceuticals (NASDAQ:BLCM) announces positive interim data from its Phase 1/2 GoCAR-T clinical trials, in the first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated in the clinical trial for BPX-601. Shares down 8.3% premarket at $1.55. BPX-601 GoCAR-T in mCRPC (first three-patient cohort): A confirmed partial response was observed in one patient, accompanied by substantial reduction in PSA in response to treatment with BPX-601 and rimiducid. No dose-limiting toxicities were observed. BPX-603 Dual-Switch GoCAR-T in HER2+ Solid Tumors: No dose-limiting toxicities were observed. Limited cell engraftment and expansion were observed. Serious adverse events reported were pleural effusion and pneumonia. Neither was determined to be related to study drug. No CRS or ICANS events were reported. Enrollment is ongoing in the second dose cohort in mCRPC of 5x106 cells/kg and at dose level 2 of 1x106 cells/kg alone, followed by weekly rimiducid in each of the study. Bellicum has also entered

For further details see:

Bellicum Pharma reports positive BPX-601 data in prostate cancer; secures $35M capital